Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J A Punt

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Onkologie|January 8, 2004
Statistical trial designs and clinical practice: are they compatible?C J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2005
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?C J A Punt
Onkologie|December 11, 2002
Performing phase III clinical trials: never an easy taskC J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
New options and old dilemmas in the treatment of patients with advanced colorectal cancerC J A Punt
Nederlands Tijdschrift Voor Geneeskunde|July 14, 2005
[Chemotherapy of patients with colorectal carcinoma]C J A Punt
The Netherlands Journal of Medicine|May 17, 2006
Treatment of liver metastases from colorectal cancerJ Tol, C J A Punt
Expert Opinion on Pharmacotherapy|May 10, 2016
Oral drugs in the treatment of metastatic colorectal cancerJ J M Kwakman, C J A Punt
European Journal of Cancer (Oxford, England : 1990)|April 30, 2002
Biological therapy of colorectal cancerE M H A de Kleijn, C J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancerC J A Punt, C D Blanke, J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancerL Mol, M Koopman, P B Ottevanger, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Onkologie|January 8, 2004
Statistical trial designs and clinical practice: are they compatible?C J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2005
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?C J A Punt
Onkologie|December 11, 2002
Performing phase III clinical trials: never an easy taskC J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
New options and old dilemmas in the treatment of patients with advanced colorectal cancerC J A Punt
Nederlands Tijdschrift Voor Geneeskunde|July 14, 2005
[Chemotherapy of patients with colorectal carcinoma]C J A Punt
The Netherlands Journal of Medicine|May 17, 2006
Treatment of liver metastases from colorectal cancerJ Tol, C J A Punt
Expert Opinion on Pharmacotherapy|May 10, 2016
Oral drugs in the treatment of metastatic colorectal cancerJ J M Kwakman, C J A Punt
European Journal of Cancer (Oxford, England : 1990)|April 30, 2002
Biological therapy of colorectal cancerE M H A de Kleijn, C J A Punt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancerC J A Punt, C D Blanke, J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancerL Mol, M Koopman, P B Ottevanger, et al.
Pageof 12